Early adult death rates remain higher than expected post-pandemic

New research from the University of Minnesota and Boston University School of Public Health (BUSPH) shows that death rates for early adults, or adults aged 25-44, rose sharply during the COVID-19 pandemic and remain higher than expected post-pandemic.

BMS strengthens NSCLC market share with ROS1 drug Augtyro – Pharmaceutical Technology

Share this article The Phase I/II TRIDENT-1, which is evaluating Augtyro (repotrectinib) is expected to be completed by February 2028. Credit: nitpicker/Shutterstock.com The US Food

November 16, 2023

mRNA therapy shows promise for maple syrup urine disease

Researchers from the University of Pennsylvania, Perelman School of Medicine, Gene Therapy Program, and Moderna, have shown that repeated administration of lipid nanoparticle-encapsulated mRNA therapy

August 22, 2024

Cannabis Company Q4 Financials Were Not Exciting

The Public Cannabis Company Revenue & Income Tracker, managed by New Cannabis Ventures, ranks the top revenue producing cannabis companies. This update is our first since

March 16, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.